Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer.
BACKGROUND Adjuvant endocrine therapy (AET) reduces breast cancer (BC) recurrence but may adversely affect cardiometabolic health. We evaluated the association between AET adherence duration and 10-year risk of hypertension, dyslipidemia, diabetes, and mortality among postmenopausal women with early-stage hormone recep...